๐ AbCellera $ABCL rockets +41% โ single-dose hot flash drug shows 83% reduction in Phase 2
AbCellera's experimental antibody ABCL635 nailed all primary endpoints in Phase 2, cutting moderate-to-severe hot flash frequency by 83% from a single dose vs. placebo โ a potential first-in-class non-hormonal treatment for menopausal women. Vertex also just handed ABCL $28M upfront plus milestones and royalties in a new collaboration deal. CEO Carl Hansen called ABCL635 a potential blockbuster. Not financial advice. Is $ABCL the women's health biotech breakout of 2026?
โก 23 buzzing
189 views
๐ 0 subscribed
